Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Seibold, J. R.
space
  arrow  Sanders, M. E.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Recombinant Human Relaxin in the Treatment of Scleroderma

A Randomized, Double-Blind, Placebo-Controlled Trial

right arrow James R. Seibold, MD; Joseph H. Korn, MD; Robert Simms, MD; Phillip J. Clements, MD, MPH; Larry W. Moreland, MD; Maureen D. Mayes, MD, MPH; Daniel E. Furst, MD; Naomi Rothfield, MD; Virginia Steen, MD; Michael Weisman, MD; David Collier, MD; Fredrick M. Wigley, MD; Peter A. Merkel, MD, MPH; Mary Ellen Csuka, MD; Vivien Hsu, MD; Susan Rocco, BS; Mark Erikson, BS; John Hannigan, MS; W. Scott Harkonen, MD; and Martin E. Sanders, MD

6 June 2000 | Volume 132 Issue 11 | Pages 871-879

Background: Relaxin is a pregnancy-related hormone that has tissue remodeling and antifibrotic effects. Systemic sclerosis (scleroderma) is characterized by fibrosis of the skin, vasculature, and internal organs.

Objective: To assess the efficacy, safety, and dose–response effect of recombinant human relaxin in patients with scleroderma.

Design: Multicenter, parallel-group, randomized, double-blind, placebo-controlled trial.

Setting: Academic referral centers.

Patients: 68 patients who had had stable, diffuse scleroderma (moderate to severe) for less than 5 years.

Intervention: Recombinant human relaxin, 25 or 100 µg/kg of body weight per day, or placebo administered by continuous subcutaneous infusion over 24 weeks.

Measurements: Modified Rodnan skin score was the primary efficacy measure. Secondary measurements were pulmonary function, the Health Assessment Questionnaire, and other measures of scleroderma that reflected fibrosis.

Results: Patients who received 25 µg/kg of recombinant human relaxin per day had significantly lower skin scores than those who received placebo (mean change, –3.6 at 4 weeks [P = 0.021], –7.5 at 12 weeks [P < 0.001], and –8.7 at 24 weeks [P = 0.040]). Similar trends were noted in other outcome measures, including forced vital capacity, measures of oral aperture and hand extension, functional status, and global assessment. Patients who received 100 µg/kg of relaxin per day did not differ from those who received placebo. Drug-related adverse events included menometrorrhagia, reversible anemia, and complications of the subcutaneous drug administration system (site irritation and local infection).

Conclusions: Twenty-four weeks of recombinant human relaxin, 25 µg/kg per day, is associated with reduced skin thickening, improved mobility, and improved function in patients with moderate to severe diffuse scleroderma.

Author and Article Information
space

From University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, New Jersey; Boston University Medical Center and Massachusetts General Hospital, Boston, Massachusetts; University of California, Los Angeles, School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Birmingham, Alabama; Wayne State University, Detroit, Michigan; Virginia Mason Research Center, Seattle, Washington; University of Connecticut Health Center, Farmington, Connecticut; Georgetown University Medical Center, Washington, D.C.; University of California, San Diego, San Diego, California; University of Colorado Health Sciences Center, Denver, Colorado; Johns Hopkins Bayview Medical Center, Baltimore, Maryland; Medical College of Wisconsin, Milwaukee, Wisconsin; and Connetics Corp., Palo Alto, California.

Acknowledgments: The authors thank the following persons for their generous contributions to this work: Deborah McCloskey (Coordinator), University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School; Raza Jafry, MD (Subinvestigator), and Mona Jaboin and Melynn Nuite (Coordinators), Boston University Medical Center; the staff of the General Clinical Research Center at Boston University Medical Center; Rita Jepson (Coordinator), University of California, Los Angeles, School of Medicine; Tina Parkhill (Coordinator), University of Alabama at Birmingham; Massoud Soleimani, MD (Subinvestigator), and Zora Injic (Coordinator), Wayne State University; Kristen Neely (Coordinator), Virginia Mason Research Center; Dolores Vasquez-Abad, MD (Subinvestigator), and Fran Ingenito (Coordinator), University of Connecticut Health Center; Mark Brodeur (Coordinator), Georgetown University Medical Center; Paul DeMarco (Subinvestigator) and Denise Mathes (Coordinator), University of California, San Diego, Division of Rheumatology; Jann Wagner (Coordinator), University of Colorado Health Sciences Center; Barbara White, MD, and Alan Matsumoto, MD (Subinvestigators), and Gwen Leatherman (Coordinator), Johns Hopkins Bayview Medical Center; Richard P. Polisson, MD, MHS, Andree Phillips, MD, and Karen Herlyn, MD (Subinvestigators), and Beatrice Mendez (Coordinator), Massachusetts General Hospital and the Mallinckrodt General Clinical Research Center at Massachusetts General Hospital; and Judi Himmel (Coordinator), Medical College of Wisconsin. They also thank Beverly Grove, Connetics Corp., for clinical services support, and all of the patients who volunteered to participate in the study.

Grant Support: By Connetics Corp., Palo Alto, California.

Requests for Single Reprints: James R. Seibold, MD, Scleroderma Program, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, One Robert Wood Johnson Place, New Brunswick, NJ 08903-0019.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Drs. Seibold and Hsu: University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, One Robert Wood Johnson Place, New Brunswick, NJ 08903-0019.

Drs. Korn and Simms: Boston University Medical Center, 80 East Concord Street, Boston, MA 02118.

Dr. Clements: University of California, Los Angeles, School of Medicine, Division of Rheumatology, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90095-1670.

Dr. Moreland: University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 1717 Sixth Avenue South, Room 068, Birmingham, AL 35294-7201.

Dr. Mayes: Wayne State University, 4707 St. Antoine Boulevard, Detroit, MI 48201.

Dr. Furst: Virginia Mason Research Center, 1000 Seneca Street, Seattle, WA 98101.

Dr. Rothfield: University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1310.

Dr. Steen: Division of Rheumatology, Immunology, and Allergy, Georgetown University Medical Center, 3800 Reservoir Road, NW, LL Gorman Building, Washington, DC 20007-2197.

Dr. Weisman: Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite B131, Los Angeles, CA 90048.

Dr. Collier: University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box E115, Denver, CO 80262.

Dr. Wigley: Johns Hopkins Bayview Medical Center, 5501 Hopkins Bayview Circle, JHAAC 3B.24, Baltimore, MD 21224.

Dr. Merkel: Boston University Medical Center, 80 East Concord Street, Boston, MA 02118.

Dr. Csuka: Medical College of Wisconsin, Division of Rheumatology, FMLH East 650, 9200 West Wisconsin Avenue, Milwaukee, WI 53226.

Ms. Rocco, Mr. Erikson, Mr. Hannigan, and Drs. Harkonen and Sanders: Connetics Corp., 3400 West Bayshore Road, Palo Alto, CA 94303.

Author Contributions: Conception and design: J.R. Seibold, R. Simms, P.J. Clements, M.D. Mayes, D.E. Furst, P.A. Merkel, S. Rocco, J. Hannigan, W.S. Harkonen, M.E. Sanders.

Analysis and interpretation of the data: J.R. Seibold, J.H. Korn, R. Simms, D.E. Furst, P.A. Merkel, S. Rocco, J. Hannigan, W.S. Harkonen, M.E. Sanders.

Drafting of the article: J.R. Seibold, F.M. Wigley, S. Rocco, J. Hannigan, M.E. Sanders.

Critical revision of the article for important intellectual content: J.R. Seibold, J.H. Korn, R. Simms, P.J. Clements, L.W. Moreland, M.D. Mayes, D.E. Furst, N.F. Rothfield, V. Steen, M. Weisman, F.M. Wigley, P.A. Merkel, M.E. Csuka, V. Hsu, S. Rocco, M. Erikson, J. Hannigan, M.E. Sanders.

Final approval of the article: J.R. Seibold, J.H. Korn, R. Simms, P.J. Clements, L.W. Moreland, M.D. Mayes, D.E. Furst, N.F. Rothfield, V. Steen, M. Weisman, D.H. Collier, F.M. Wigley, P.A. Merkel, M.E. Csuka, V. Hsu, S. Rocco, M. Erikson, M.E. Sanders.

Provision of study materials or patients: J.R. Seibold, J.H. Korn, R. Simms, P.J. Clements, L.W. Moreland, M.D. Mayes, D.E. Furst, N.F. Rothfield, V. Steen, M. Weisman, D.H. Collier, F.M. Wigley, P.A. Merkel, M.E. Csuka, V. Hsu.

Statistical expertise: J. Hannigan.

Obtaining of funding: M.E. Sanders.

Administrative, technical, or logistic support: S. Rocco, M. Erikson, M.E. Sanders.

Collection and assembly of data: J.R. Seibold, R. Simms, F.M. Wigley, P.A. Merkel, S. Rocco.


Related articles in Annals:

Summaries for Patients
Using a Pregnancy-Related Hormone, Relaxin, to Treat Scleroderma
Annals 2000 132: 871. [Full Text]  



This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, and V. Rivera
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide
Rheumatology, January 1, 2009; 48(1): 49 - 52.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
I. Badea, M. Taylor, A. Rosenberg, and M. Foldvari
Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis
Rheumatology, November 20, 2008; (2008) ken405v1.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
C V Tehlirian, L K Hummers, B White, R A Brodsky, and F M Wigley
High-dose cyclophosphamide without stem cell rescue in scleroderma
Ann Rheum Dis, June 1, 2008; 67(6): 775 - 781.
[Abstract] [Full Text] [PDF]


Home page
Am J Sports MedHome page
S. Negishi, Y. Li, A. Usas, F. H. Fu, and J. Huard
The Effect of Relaxin Treatment on Skeletal Muscle Injuries
Am. J. Sports Med., December 1, 2005; 33(12): 1816 - 1824.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. R. Johnson and P. Lee
The HAQ disability index in scleroderma trials
Rheumatology, September 1, 2004; 43(9): 1200 - 1201.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
O. D. Sherwood
Relaxin's Physiological Roles and Other Diverse Actions
Endocr. Rev., April 1, 2004; 25(2): 205 - 234.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
A. N. Sapadin and R. Fleischmajer
Treatment of Scleroderma
Arch Dermatol, January 1, 2002; 138(1): 99 - 105.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. J. Gross and G. W. Hunninghake
Idiopathic Pulmonary Fibrosis
N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Simons
Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi?
Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H1923 - H1927.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
Robin Goodfellow
Rheumatology, September 1, 2000; 39(9): 1050 - 1050.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
Robin Goodfellow
Rheumatology, August 1, 2000; 39(8): 932 - 932.
[Full Text] [PDF]


Home page
Journal Watch DermatologyHome page
Regressing Systemic Sclerosis?
Journal Watch Dermatology, July 10, 2000; 2000(710): 1 - 1.
[Full Text]


Home page
JWatch GeneralHome page
Relaxin Therapy in Scleroderma
Journal Watch (General), July 7, 2000; 2000(707): 7 - 7.
[Full Text]


Home page
JWatch GeneralHome page
A Treatment for Scleroderma?
Journal Watch (General), June 20, 2000; 2000(620): 2 - 2.
[Full Text]


Home page
J. Biol. Chem.Home page
E. E. Bullesbach and C. Schwabe
The Relaxin Receptor-binding Site Geometry Suggests a Novel Gripping Mode of Interaction
J. Biol. Chem., November 3, 2000; 275(45): 35276 - 35280.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2000 by the American College of Physicians.